Description
ARA 290 is a derivative of erythropoietin (EPO).1 In vivo, ARA 290 (0.8 and 8 nmol/kg, i.p.) reduces plasma creatine, urea, and aspartate aminotransferase (AST) levels, markers of renal dysfunction, in a rodent model of renal ischemia-reperfusion injury. It decreases wound area in a rat model of punch biopsy-induced dermal injury and a rat model of decubitus ulcer.2 ARA 290 (30 µg/kg, i.p.) reduces the latency to find the platform in the Morris water maze in a rat model of cortical impact-induced traumatic brain injury (TBI).3 It also reduces tactile allodynia in a rat model of neuropathic pain induced by spinal nerve injury (SNI).4WARNING This product is not for human or veterinary use.
References
[1] MICHAEL BRINES. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin.[J]. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105 31: 10925-10930. DOI:
10.1073/pnas.0805594105[2] ZÜBEYDE ERBAYRAKTAR. Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing.[J]. Molecular Medicine, 2009, 15 7-8: 235-241. DOI:
10.2119/molmed.2009.00051[3] CLAUDIA S ROBERTSON. Treatment of mild traumatic brain injury with an erythropoietin-mimetic peptide.[J]. Journal of neurotrauma, 2013, 30 9: 765-774. DOI:
10.1089/neu.2012.2431[4] MAARTEN SWARTJES Albert D Marieke Niesters. Assessment of allodynia relief by tissue-protective molecules in a rat model of nerve injury-induced neuropathic pain.[J]. Methods in molecular biology, 2013, 982: 187-195. DOI:
10.1007/978-1-62703-308-4_12
